Clinical Trial Update: S0354, Anti-IL-6 Chimeric Monoclonal Antibody in Patients With Metastatic Prostate Cancer That Did Not Respond to Hormone Therapy [Phase 2]

View source ↗

Summary

Phase 2 trial of S0354, an anti-IL-6 chimeric monoclonal antibody, in metastatic prostate cancer that did not respond to hormone therapy; the study is completed…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Prostate Cancer

Drugs mentioned

• S0354 anti-IL-6 chimeric monoclonal antibody

Snippet

Sponsor: SWOG Cancer Research Network | Conditions: Prostate Cancer | Phase 2 | Status: COMPLETED | Results posted: 2013-02-05